Despite the role of MET signaling in tumor angiogenesis [24, 25, 45] and the possible therapeutic benefit of targeting MET aberrant expression in liver tumors, the impact of MET inhibition on liver cancer-associated angiogenesis has not been yet adequately reported. The gene discussed is MET; the disease is neoplasm.